2010 Scrip 100 - The flu pandemic: mild at first, but could turn nasty
This article was originally published in Scrip
Executive Summary
The swine flu pandemic shook up national governments and their populations in 2009, but H1N1 proved to be a boon for manufacturers of antiviral products, notably Roche and GlaxoSmithKline. Meanwhile, other companies are planning new kinds of vaccines to cope with future flu outbreaks, reports Ian Schofield.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.